BR112021022685A2 - Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridina-3-carboxamida - Google Patents

Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridina-3-carboxamida

Info

Publication number
BR112021022685A2
BR112021022685A2 BR112021022685A BR112021022685A BR112021022685A2 BR 112021022685 A2 BR112021022685 A2 BR 112021022685A2 BR 112021022685 A BR112021022685 A BR 112021022685A BR 112021022685 A BR112021022685 A BR 112021022685A BR 112021022685 A2 BR112021022685 A2 BR 112021022685A2
Authority
BR
Brazil
Prior art keywords
fluorocyclopropyl
imidazo
methylphenyl
carboxamide
pyridine
Prior art date
Application number
BR112021022685A
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas Kordikowski
Xiaoyang Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112021022685A2 publication Critical patent/BR112021022685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021022685A 2019-05-13 2020-05-13 Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridina-3-carboxamida BR112021022685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019086582 2019-05-13
PCT/CN2020/090060 WO2020228746A1 (en) 2019-05-13 2020-05-13 Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide

Publications (1)

Publication Number Publication Date
BR112021022685A2 true BR112021022685A2 (pt) 2022-03-29

Family

ID=73289607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022685A BR112021022685A2 (pt) 2019-05-13 2020-05-13 Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridina-3-carboxamida

Country Status (14)

Country Link
US (1) US20220194936A1 (enExample)
EP (1) EP3969453A4 (enExample)
JP (1) JP2022533340A (enExample)
KR (1) KR20220007650A (enExample)
CN (1) CN114096538A (enExample)
AU (1) AU2020274564A1 (enExample)
BR (1) BR112021022685A2 (enExample)
CA (1) CA3139552A1 (enExample)
IL (1) IL287877A (enExample)
MA (1) MA55976A (enExample)
MX (1) MX2021013814A (enExample)
SG (1) SG11202112281UA (enExample)
TW (1) TW202108581A (enExample)
WO (1) WO2020228746A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534963A (ja) * 2020-07-15 2023-08-15 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態
TW202237096A (zh) * 2020-11-19 2022-10-01 瑞士商諾華公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
EP4626884A1 (en) 2022-11-30 2025-10-08 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
CN122580315A (zh) * 2024-01-04 2026-08-14 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2845785A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN103930424A (zh) * 2011-09-01 2014-07-16 Irm责任有限公司 作为c-Kit激酶抑制剂的化合物和组合物
US8569283B2 (en) * 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors

Also Published As

Publication number Publication date
SG11202112281UA (en) 2021-12-30
CA3139552A1 (en) 2020-11-19
AU2020274564A1 (en) 2021-12-09
CN114096538A (zh) 2022-02-25
TW202108581A (zh) 2021-03-01
MX2021013814A (es) 2022-02-10
US20220194936A1 (en) 2022-06-23
WO2020228746A1 (en) 2020-11-19
EP3969453A4 (en) 2023-01-18
MA55976A (fr) 2022-03-23
IL287877A (en) 2022-01-01
KR20220007650A (ko) 2022-01-18
JP2022533340A (ja) 2022-07-22
EP3969453A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
MX2021013814A (es) Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
PH12019502853A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
RU2017114346A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
CY1119813T1 (el) Αλατα 2-φθορο-ν-μεθυλ-4-[7-(κινολιν-6-υλ-μεθυλ)-ιμιδαζο[1,2-β][1,2,4]τριαζιν-2-υλ]βενζαμιδιου και διαδικασιες που σχετιζονται με την παρασκευη αυτων
PE20220964A1 (es) Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas
RU2016141569A (ru) Комбинации
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
JO3616B1 (ar) تركيبات دوائية من إيتيكسيلات دابيجاتران تعطى بالفم
JP2012180381A5 (enExample)
BR112012020557A2 (pt) formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio.
FI3700529T3 (fi) Uusi aktiivisten aineiden yhdistelmä etenevien fibrotisoivien interstitiaalisten keuhkosairauksien (pf-ild) hoitoon
JP2015517488A5 (enExample)
UY37328A (es) Compuestos diazaheterobicíclicos sustituidos y su uso
AR107798A1 (es) Compuestos derivados de piridazin y sus composiciones farmacéuticas para el tratamiento de la fibrosis
JP2019511542A (ja) カプシド集合阻害剤を含む組み合わせ及び方法
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
WO2015116856A3 (en) Farnesoid x receptor antagonists
BR112022007721A2 (pt) Método para o tratamento da demência
AR103176A1 (es) Formulaciones farmacéuticas de inhibidores de la cinasa relacionada con tropomiosina (trk)
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
SA518400501B1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2880 DE 17-03-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.